蛛网膜下腔出血(SAH)是神经内科常见病之一。现普遍认为SAH所致的脑血管痉挛(CVS)是致死致残的主要原因。以往常规给予镇静、止血及脱水剂治疗,其所致的病死率较高、合并症多。自1998—2007年,本研究用尼莫地平治疗SAH,既缩短了病程,也降低了病死率,同时还减少了并发症和后遗症 Subarachnoid hemorrhage (SAH) is one of the most common neurological diseases. It is generally accepted that SAH-induced cerebral vasospasm (CVS) is the leading cause of death and disability. In the past to give sedation, hemostasis and dehydration agent treatment, which caused a higher mortality, complications and more. Since 1998-2007, the study of nimodipine in the treatment of SAH, both shorten the course of disease, but also reduce the case fatality rate, while reducing the complications and sequelae